Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug:40:52-59.
doi: 10.1016/j.mcp.2018.01.001. Epub 2018 Jan 5.

Modeling rare diseases with induced pluripotent stem cell technology

Affiliations
Review

Modeling rare diseases with induced pluripotent stem cell technology

Ruthellen H Anderson et al. Mol Cell Probes. 2018 Aug.

Abstract

Rare diseases, in totality, affect a significant proportion of the population and represent an unmet medical need facing the scientific community. However, the treatment of individuals affected by rare diseases is hampered by poorly understood mechanisms preventing the development of viable therapeutics. The discovery and application of cellular reprogramming to create novel induced pluripotent stem cell models of rare diseases has revolutionized the rare disease community. Through developmental and functional analysis of differentiated cell types, these stem cell models carrying patient-specific mutations have become an invaluable tool for rare disease research. In this review article, we discuss the reprogramming of samples from individuals affected with rare diseases to induced pluripotent stem cells, current and future applications for this technology, and how integration of genome editing to rare disease research will help to improve our understanding of disease pathogenesis and lead to patient therapies.

Keywords: CRISPR; Disease modeling; Induced pluripotent; Pluripotency; Rare disease; iPSC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
iPSC generation and potential uses of iPSC-derivatives for rare disease studies.

References

    1. de la Paz MP, et al. Rare diseases epidemiology research. Adv Exp Med Biol. 2010;686:17–39. - PubMed
    1. Melnikova I. Rare diseases and orphan drugs. Nat Rev Drug Discov. 2012;11(4):267–8. - PubMed
    1. EURODIS - Rare Diseases Europe [Internet]. Paris (France); [updated 2014 Sep; cited 2017 Dec 22]. Available from: https://www.eurordis.org/sites/default/files/publications/Fact_Sheet_RD.pdf.

    1. Bartlett JR, et al. Genetic modifiers of liver disease in cystic fibrosis. Jama. 2009;302(10):1076–83. - PMC - PubMed
    1. Kochanek Kenneth D, MA, Murphy Sherry L, BS, Xu Jiaquan, MD, Tejada-Vera B. Deaths: Final Data for 2014. National Vital Statistics Reports. 2016;65(4) - PubMed

Publication types